Endometrial Carcinoma – Landscape & Forecast – Disease Landscape & Forecast
Chemotherapy and hormonal therapy have been the mainstay treatments of advanced endometrial carcinoma, but treatment is becoming more directed, as a result of tumor analysis. Immune checkpoint inhibitors (e.g., Merck & Co.’s Keytruda) and targeted therapies (e.g., Eisai’s Lenvima) are experiencing uptake. Some agents target specific biomarker-defined populations, such as MSI-H or dMMR, and others target all patients. The approval and uptake of these agents will result in a more-personalized approach to treating advanced endometrial carcinoma. Several agents are also being positioned for the untapped first-line setting (e.g., GSK/Tesaro’s dostarlimab, Karyopharm’s Xpovio, AstraZeneca’s Lynparza) and will contribute to robust market growth over the 2019-2029 forecast period.
Questions Answered
- How large are the clinically and commercially relevant drug-treatable endometrial carcinoma populations, and how will drug-treatment rates change over time?
- What is the expected market impact of recent drug approvals, such as Keytruda and Lenvima, for endometrial carcinoma?
- Which pipeline products are poised to become options for the treatment of endometrial carcinoma, and what sales / uptake will they secure?
- What are the key drivers and constraints in the endometrial carcinoma market, and how will the major markets evolve over the ten-year forecast period?
Content Highlights
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: 19 country-specific interviews with thought-leading medical oncologists.
Epidemiology: Diagnosed incident of endometrial carcinoma by country, disease stage, and risk status.
Forecast: 10-year, annualized, drug- and regimen-level sales and patient share of key endometrial cancer therapies through 2029, segmented by brands / biosimilars / generics, disease stage, and country.
Emerging therapies: Phase III/PR: 5 drugs; coverage of select early-phase products.
Product Description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution Enhancement
Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Table of contents
- Endometrial Carcinoma - Landscape & Forecast - Disease Landscape & Forecast
- Key Updates
- Q4 2021
- December 2021
- November 2021
- October 2021
- Q3 2021
- September 2021
- August 2021
- July 2021
- Q2 2021
- June 2021
- May 2021
- April 2021
- Q1 2021
- Q4 2021
- Key Findings
- Endometrial Carcinoma Key Findings - March 2021
- Endometrial Carcinoma Key Findings - March 2021
- Market Outlook
- Key Findings
- Major-Market Share of Drug Classes for Endometrial Carcinoma: 2019
- Major-Market Share of Drug Classes for Endometrial Carcinoma: 2029
- Major-Market Sales of Key Therapies for Endometrial Carcinoma: 2019-2029
- Drug-Treatable Population Share and Major-Market Sales Share in Endometrial Carcinoma: 2019
- Drug-Treatable Population Share and Major-Market Sales Share in Endometrial Carcinoma: 2029
- Positioning of Key Therapies in Endometrial Carcinoma in the United States: 2019-2029
- Population Positioning of Therapies in Endometrial Carcinoma
- SWOT Analysis
- COVID-19: Areas of Potential Forecast Impact
- Market Drivers and Constraints
- What Factors Are Driving the Market for Endometrial Carcinoma?
- What Factors Are Constraining the Market for Endometrial Carcinoma?
- Segment-Specific Trends
- Patient Share Dynamics of Key Agents in Early-Stage Endometrial Carcinoma in the United States: 2019-2029
- Patient-Share Dynamics of Key Agents in First-Line Advanced or Recurrent Endometrial Carcinoma in the United States: 2019-2029
- Patient-Share Dynamics of Key Agents in Second-Line Advanced or Recurrent Endometrial Carcinoma in the United States: 2019-2029
- Patient-Share Dynamics of Key Agents in Third-Line Advanced or Recurrent Endometrial Carcinoma in the United States: 2019-2029
- Key Findings
- Forecast
- Market Forecast Assumptions
- Market Forecast Dashboard
- Etiology and Pathophysiology
- Disease Overview
- Disease Pathophysiology
- Anatomy of the Uterus
- Anatomy of the Uterus
- Prognostic Biomarkers in Endometrial Cancer
- Prognostic Biomarkers in Endometrial Cancer
- Staging and Classification
- Classification of Endometrial Cancer
- AJCC Prognostic Stage Groups for Endometrial Cancer
- AJCC TNM and FIGO Surgical Staging Systems for Endometrial Cancer
- Key Pathways and Drug Targets
- Key Pathways and Drug Targets in Endometrial Cancer
- Immune Checkpoint Inhibitors and Modulators
- PARP Inhibition: Mechanism of Action
- Disease Overview
- Epidemiology
- Key Findings
- Epidemiology Populations
- Disease Definition
- Methods
- Sources Used for Diagnosed Incidence of Endometrial Carcinoma
- Diagnosed Incident Cases of Endometrial Carcinoma: 2019-2029
- Disease Definition
- Methods
- Sources Used for Stage Distribution of Endometrial Carcinoma
- Diagnosed Incident Cases of Endometrial Carcinoma by Stage Distribution: 2019-2029
- Definition
- Methods
- Sources Used for Recurrent Incidence of Endometrial Carcinoma
- Recurrent Incident Cases of Endometrial Carcinoma: 2019-2029
- Endometrial Carcinoma Patient Flow
- Drug-Treatable Cases of Endometrial Carcinoma: 2019-2029
- Drug-Treated Cases of Endometrial Carcinoma: 2019-2029
- Key Findings
- Current Treatment
- Key Findings
- Treatment Goals
- Key Endpoints Used in Clinical Trials for Endometrial Carcinoma
- Key Current Therapies
- Overview
- Mechanism of Action of Key Current Drug Classes Used for Endometrial Carcinoma
- Current Treatments Used for Endometrial Carcinoma
- Market Events Impacting the Use of Key Current Therapies for Endometrial Carcinoma
- Keytruda
- Key Results From Select Clinical Trials Investigating Keytruda for the Treatment of Endometrial Carcinoma
- Ongoing Clinical Development of Keytruda
- Key Ongoing Clinical Trials of Keytruda in the Treatment of Endometrial Carcinoma
- Expert Insight: Keytruda
- Jemperli
- Key Results From Select Clinical Trials Investigating Jemperli for the Treatment of Endometrial Carcinoma
- Ongoing Clinical Development of Jemperli
- Key Ongoing Trials of Jemperli in the Treatment of Endometrial Carcinoma
- Expert Insight: Jemperli
- Lenvima
- Ongoing Clinical Development of Lenvima
- Expert Insight: Lenvima
- Hormonal Agents
- Expert Insight: Hormonal Agents
- Medical Practice
- Newly Diagnosed Early-Stage (Stage I-II) Endometrial Carcinoma
- First-Line Advanced or Recurrent Endometrial Carcinoma
- Second- and Later-Line Advanced or Metastatic Endometrial Carcinoma
- Country-Specific Endometrial Carcinoma Treatment Guidelines
- Patient Characteristics Influencing Drug Selection in Endometrial Carcinoma
- Treatment Decision Tree for Newly Diagnosed (Early-Stage) Endometrial Carcinoma: G7
- Treatment Decision Tree for Endometrial Carcinoma: United States
- Treatment Decision Tree for Endometrial Carcinoma: Europe
- Treatment Decision Tree for Endometrial Carcinoma: Japan
- Key Findings
- Unmet Need Overview
- Current and Future Attainment of Unmet Needs in Endometrial Carcinoma
- Top Unmet Needs in Endometrial Carcinoma: Current and Future Attainment
- Expert Insight: Unmet Need in Endometrial Carcinoma
- Emerging Therapies
- Key Findings
- Pipeline Trends in Endometrial Carcinoma
- Key Emerging Therapies
- Key Therapies in Development for Endometrial Carcinoma
- Estimated Market Authorization Dates of Key Emerging Therapies for the Treatment of Endometrial Carcinoma
- Key Results from Select Clinical Trials Investigating Tecentriq for the Treatment of Endometrial Carcinoma
- Key Ongoing Trials of Tecentriq in the Treatment of Endometrial Carcinoma
- Analysis of the Clinical Development Program for Tecentriq
- Expert Insight: Tecentriq
- Expectations for Market Authorization and Sales Opportunity of Tecentriq in Endometrial Carcinoma
- Key Results from Select Clinical Trials Investigating Imfinzi for the Treatment of Endometrial Carcinoma
- Key Ongoing Trials of Imfinzi in the Treatment of Endometrial Carcinoma
- Analysis of the Clinical Development Program for Imfinzi
- Expert Insight: Imfinzi
- Expectations for Market Authorization and Sales Opportunity of Imfinzi in Endometrial Carcinoma
- Key Results from Select Clinical Trials Investigating Xpovio for the Treatment of Endometrial Carcinoma
- Key Ongoing Trials of Xpovio in the Treatment of Endometrial Carcinoma
- Analysis of the Clinical Development Program for Xpovio
- Expert Insight: Xpovio
- Expectations for Market Authorization and Sales Opportunity of Xpovio in Endometrial Carcinoma
- Analysis of the Clinical Development Program for Lynparza
- Expert Insight: Lynparza
- Expectations for Market Authorization and Sales Opportunity of Lynparza in Endometrial Carcinoma
- Key Ongoing Clinical Trials of EG-007 in the Treatment of Endometrial Carcinoma
- Analysis of the Clinical Development Program for EG-007
- Expectations for Market Authorization and Sales Opportunity of EG-007 in Endometrial Carcinoma
- Early-Phase Pipeline Analysis
- Select Compounds in Early-Phase Development for Endometrial Cancer
- Key Findings
- Access & Reimbursement Overview
- Region-Specific Reimbursement Practices
- Key Market Access Considerations in Endometrial Carcinoma: United States
- General Reimbursement Environment: United States
- Key Market Access Considerations in Endometrial Carcinoma: EU5
- General Reimbursement Environment: EU5
- Key Market Access Considerations in Endometrial Carcinoma: Japan
- General Reimbursement Environment: Japan
- Region-Specific Reimbursement Practices
- Appendix
- Key Abbreviations Related to Endometrial Carcinoma
- Brands, Marketers, and Generic Availability of Key Therapies for Endometrial Carcinoma: by Market
- Endometrial Carcinoma Bibliography
- Key Updates
Laura Vinuesa, D.V.M., M.Sc., is a senior business insights analyst on the Oncology team at Clarivate. She specializes in bladder cancer and head and neck cancers and in optimizing market access opportunities for new biomarker-targeted therapies in oncology. Previously, she was part of the Global Market Access Insights team, for whom she analyzed the healthcare systems and pharmaceutical markets of the EU5 and focused on evolving HTA demands, P&R processes, and stringent cost-containment strategies. She obtained her doctorate in veterinary medicine from Complutense University in Madrid and a master’s degree in clinical research and pharmaceutical medicine from EPHOS Business School in Madrid.